Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.
Company codePTPI
Company namePetros Pharmaceuticals Inc
IPO dateDec 02, 2020
Founded at2020
CEO- -
Number of employees18
Security typeOrdinary Share
Fiscal year-endDec 02
Address1185 Avenue Of The Americas, 3Rd Floor
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10036
Phone19732420005
Websitehttps://www.petrospharma.com/
Company codePTPI
IPO dateDec 02, 2020
Founded at2020
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data